BDSX

7.5608.92%
SH

Scott Hutton

President, CEO & Director

Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 2019. Mr. Hutton has been Director of Eximis Surgical since February 2018 and was an Observer on the Board of Directors of Aqueduct Critical Care from September 2014 to January 2017, and an Observer on the Board of Visualase, Inc. from October 2012 to July 2014. He had been General Manager of Vascular Intervention at The Spectranetics Corporation since January 23, 2017 until December 2017 and its Senior Vice President since January 2017 until December 2017. Mr. Hutton served as Senior Director of Global Marketing and Business Leader of the Surgical Navigation and Intra-Operative Imaging Business at Medtronic Navigation from 2008 to 2012. He has a wealth of industry experience and leadership. He served as Head of Global Marketing for Medtronic Navigation since November 2008. He spent several years with Medtronic, most recently leading the Neurosurgery business unit and served as the Vice President and General Manager from April 2012 to January 2017. He lead the global marketing activities for the Louisville, Colorado-based medical company, which is the leading provider of integrated navigation and intra-operative imaging solutions in the world. Mr. Hutton joined Medtronic in 2000 and progressed through positions of increasing responsibility in Marketing and Business Development in Medtronic Spinal and Biologics business located in Memphis, TN. He served as Director of Business Development. Prior to Medtronic, he worked for an orthopedic medical device distributor representing DePuy Orthopaedics (a Member of the Johnson & Johnson family of companies) and Biomet. He served as Director of Colorado Bioscience Association from April 2011 to April 2013. Mr. Hutton holds a Bachelor of Arts degree from the College of Health and Human Sciences, Department of Health and Kinesiology at Purdue University. In March 2021, Mr. Hutton was named a Significant Sig by Sigma Chi International Fraternity. In February 2021, Mr. Hutton was named a Top 25 Biotech CEO of 2021 by the Healthcare Technology Report. In January 2021, he was named 2020 CEO of the Year-USA by CEO Monthly Magazine. In July 2011, he received the Medtronic Wallin Leadership Award for his focus on talent development, business performance, and his personal and intentional demonstration of leadership.

Positions